The Company views use of the Flaskworks closed system as key to enabling DCVax-L production to begin taking place in Grade C suites rather than Grade B suites – and the Company views such transition to Grade C suites as central to large scale-up of production.
DCVAXL is the intended commercial route and therefore must be certified to be able for the MAA to be granted. Thats it
I don't read this the way you do. "Central to large scale up of production" does not equal "central to commercialization" in my book.
Commercialization can be achieved in the UK with their Grade B room, artisan process. The "large scale up" would be expansion following said commercialization launch.